18 December 2025 in European Respiratory Journal
Question: Chronic lung allograft dysfunction (CLAD) is the leading cause of late graft failure after lung transplantation. Fibroblast activation protein (FAP) is selectively upregulated in activated fibroblasts under fibrotic conditions. We asked whether FAP expression is increased in CLAD and whether it can serve as an early diagnostic marker. Materials and methods: We performed single-cell RNA sequencing on two murine orthotopic lung transplant models (C57BL/6→C57BL/10 and BALB/c→C57BL/6) and human lung tissue from five controls and five patients with CLAD. We quantified FAP expression by immunohistochemistry in transbronchial biopsies from 240 lung transplant recipients (62 with CLAD and 178 without CLAD). Receiver-operating characteristic curves determined an optimal FAP-positive area threshold. Kaplan–Meier analysis and Cox proportional hazards models assessed the association between FAP positivity and CLAD. Results: In both murine and human single-cell data, FAP expression was confined to pathogenic fibroblast subsets and was significantly elevated in CLAD. In the clinical cohort, a threshold of 10.8% FAP-positive area discriminated chronic dysfunction with an area under the curve of 0.78 (95% CI 0.72–0.85), sensitivity of 65% and specificity of 84%. FAP positivity predicted shorter CLAD-free survival (p<0.0001) and overall survival (p=0.03). The hazard ratio for CLAD was 5.23 (95% CI 3.11–8.82; p<0.001), remaining significant after multivariable adjustment (hazard ratio 5.43, 95% CI 3.22–9.16; p<0.001). Answer: FAP expression is elevated in CLAD and is associated with subsequent CLAD and survival. Tissue FAP may enable early risk stratification and inform clinical surveillance; however, given its moderate discrimination, prospective validation in multicentre cohorts is warranted.
21 August 2024 in Cancer Science
Thymic epithelial tumors (TETs) are rare tumors arising from the mediastinum. Among TETs, thymoma type B2, B3 and thymic carcinoma are highly malignant and often present invasion and dissemination. However, the biological characteristics of TETs have not been thoroughly studied, and their mechanisms of invasion and dissemination are largely unknown. α‐Actinin 4 (ACTN4) is a member of actin‐binding proteins and reportedly plays important roles in the progression of several cancers. In this study, we investigated the relationship between ACTN4 and characteristics of the malignant potential of TETs, such as invasion and dissemination. In vitro experiments using Ty‐82 thymic carcinoma cells revealed that overexpression of ACTN4 enhanced the proliferative and invasive ability of Ty‐82 cells; conversely, knockdown of ACTN4 attenuated the proliferative and invasive potential of Ty‐82 cells. In western blotting (WB) experiments, ACTN4 induced the phosphorylation of extracellular signal–regulated kinase and glycogen synthase kinase 3β to regulate the β‐catenin/Slug pathway. Furthermore, WB analysis of cancer tissue–origin spheroids from patients with TETs showed results similar to those for Ty‐82 cells. In vivo experiments showed that the knockdown of ACTN4 significantly suppressed the dissemination of Ty‐82 cells. A WB and immunohistochemistry staining comparison of primary and disseminated lesions of TETs using surgical specimens showed upregulated expression of ACTN4, β‐catenin, and Slug proteins in disseminated lesions. In summary, our study suggests ACTN4 is associated with malignant potential characteristics such as invasion and dissemination in TETs via the β‐catenin/Slug pathway.
9 December 2025 in Pathology International
1 January 2026 in Asian Journal of Endoscopic Surgery
20 September 2026 in Cancer Science
Cancer‐associated fibroblasts (CAFs) have been recognized as key contributors to tumor progression. Chimeric antigen receptor (CAR) T‐cell therapy targeting fibroblast activation protein (FAP), a marker of CAFs, has gained attention and is being evaluated in both preclinical and clinical studies. Cord blood (CB)‐derived CAR natural killer (NK) cell therapy has shown efficacy in hematologic malignancies. In this study, we generated FAP‐targeting CAR NK cells (FAP‐CAR NK cells). CD3‐depleted CB mononuclear cells were stimulated with irradiated K562 cells expressing 4‐1BB ligand (tumor necrosis factor ligand superfamily member 9) and membrane‐bound interleukin‐15 and interleukin‐21 to expand NK cells, into which FAP‐CAR was introduced. FAP‐CAR NK cells produced cytokines and exerted cytotoxic activity when co‐cultured with FAP‐transduced HT1080 cells and CAFs isolated from human lung cancer tissue. In a xenograft model established by intrathoracic co‐injection of A549 lung cancer cells and luciferase‐expressing CAFs, injection of FAP‐CAR NK cells, but not control CD19‐CAR NK cells, resulted in their robust expansion and persistence in vivo for 5 weeks. However, CAFs were not eliminated by FAP‐CAR NK cells, although CAR NK cells were clearly detected in the tumors. The levels of cytotoxicity‐associated molecules (such as granzymes) were higher in FAP‐CAR NK cells persisting in the spleens of mice compared with those in pre‐infusion FAP‐CAR NK cells. These results indicate that FAP‐CAR NK cells have the potential to respond specifically to the target antigen and expand robustly in vivo, although further optimization is required to maintain cytotoxic function for a prolonged duration in vivo.